#1 Clinical Trials Search in Europe

Navitoclax

Navitoclax is an investigational drug being studied in clinical trials for various blood cancers and myelofibrosis. This article summarizes key information about ongoing clinical trials evaluating navitoclax alone or in combination with other therapies. The trials aim to assess the safety, efficacy, and optimal dosing of navitoclax in conditions like chronic lymphocytic leukemia, acute lymphoblastic leukemia, and myelofibrosis.

Table of Contents

What is Navitoclax?

Navitoclax, also known as ABT-263, is an investigational drug being developed to treat various blood disorders[1]. It is currently being studied in clinical trials to determine its safety and effectiveness in treating different conditions. Navitoclax is part of a class of drugs called BCL-2 inhibitors, which work by targeting specific proteins in cancer cells[2].

What Conditions Does Navitoclax Treat?

Navitoclax is being investigated for the treatment of several blood disorders, including:

  • Myelofibrosis (MF): A type of bone marrow cancer that disrupts the body’s normal production of blood cells and causes bone marrow scarring[1].
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects white blood cells called lymphocytes[3].
  • Acute Lymphoblastic Leukemia (ALL): A cancer of immature lymphocytes, which are a type of white blood cell involved in the body’s immune system[4].
  • Lymphoblastic Lymphoma (LL): An aggressive form of non-Hodgkin lymphoma that affects lymphocytes[5].

How Does Navitoclax Work?

Navitoclax works by targeting and inhibiting specific proteins in cancer cells, particularly those in the BCL-2 family. These proteins help cancer cells survive and resist treatment. By blocking these proteins, Navitoclax may help to stop the growth of cancer cells and make them more susceptible to other treatments[2].

Current Clinical Trials

Navitoclax is currently being studied in various clinical trials to assess its safety and effectiveness. Some of the ongoing studies include:

  • A study combining Navitoclax with Ruxolitinib for the treatment of myelofibrosis[1].
  • An open-label extension study for patients with chronic lymphocytic leukemia[3].
  • A study evaluating Navitoclax in combination with Osimertinib for non-small cell lung cancer[2].
  • A trial assessing Navitoclax with Venetoclax for pediatric patients with relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma[5].

How is Navitoclax Administered?

Navitoclax is typically administered as an oral tablet. The dosage and frequency may vary depending on the specific condition being treated and the clinical trial protocol. In some studies, Navitoclax is given once daily, while in others, it may be combined with other medications[1][5].

Potential Side Effects

As with any medication, Navitoclax may cause side effects. Clinical trials are designed to monitor and assess these effects closely. Common side effects and safety concerns are being evaluated in ongoing studies. Patients participating in clinical trials are closely monitored for any adverse events[3].

Combination Therapy

Navitoclax is often studied in combination with other drugs to potentially enhance its effectiveness. Some combinations being investigated include:

  • Navitoclax with Ruxolitinib for myelofibrosis[1].
  • Navitoclax with Osimertinib for non-small cell lung cancer[2].
  • Navitoclax with Venetoclax for acute lymphoblastic leukemia and lymphoblastic lymphoma[5].

Future Prospects

The ongoing clinical trials for Navitoclax are aimed at determining its safety and efficacy in various blood disorders. If these trials show promising results, Navitoclax could potentially become an important treatment option for patients with these conditions. However, it’s important to note that as an investigational drug, Navitoclax is still being studied and is not yet approved for general use outside of clinical trials[6].

Aspect Details
Drug Name Navitoclax (ABT-263)
Conditions Studied Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukemia (ALL), Myelofibrosis, Lymphoblastic lymphoma
Administration Oral tablet, typically taken daily
Combination Therapies Often studied in combination with drugs like ruxolitinib, venetoclax, or osimertinib
Key Outcome Measures Safety, adverse events, spleen volume reduction, changes in blood cell counts, minimal residual disease status
Trial Phases Phase 1, Phase 2, and Phase 3 studies ongoing
Special Populations Some trials focus on pediatric patients or those with relapsed/refractory disease

FAQ

  • What is navitoclax? Navitoclax (also known as ABT-263) is an investigational drug being studied as a potential treatment for various blood cancers and myelofibrosis. It works by inhibiting certain proteins involved in cell survival.
  • What conditions is navitoclax being studied for? Clinical trials are evaluating navitoclax for conditions including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma, and myelofibrosis.
  • How is navitoclax given to patients in clinical trials? In most trials, navitoclax is given as an oral tablet that patients take daily. The exact dose and schedule can vary between trials.
  • What are some of the potential side effects of navitoclax? Common side effects being monitored in trials include changes in blood cell counts, gastrointestinal effects, and fatigue. The trials closely monitor patients for any adverse events.
  • Is navitoclax approved for use outside of clinical trials? No, navitoclax is still considered an investigational drug and is not yet approved by regulatory agencies for general use. It is only available to patients through participation in clinical trials or expanded access programs.

Ongoing Clinical Trials on Navitoclax

  • Study on the Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Croatia Greece Italy Spain

  • Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia France Germany Italy Spain

Glossary

  • Chronic lymphocytic leukemia (CLL): A slow-growing blood cancer that affects white blood cells called lymphocytes. It is the most common type of leukemia in adults.
  • Acute lymphoblastic leukemia (ALL): A fast-growing cancer of immature lymphocytes (a type of white blood cell). It is the most common childhood cancer but can also occur in adults.
  • Myelofibrosis: A rare bone marrow cancer that disrupts the body's normal production of blood cells and leads to scarring in the bone marrow.
  • Lymphoblastic lymphoma: An aggressive type of non-Hodgkin lymphoma that affects immature lymphocytes. It is similar to ALL but mainly affects lymph nodes rather than bone marrow.
  • Spleen volume reduction: A measure of treatment effectiveness in myelofibrosis, referring to a decrease in the size of the enlarged spleen often seen in this condition.
  • Minimal residual disease (MRD): Very low levels of cancer cells that remain after treatment, which can only be detected by highly sensitive tests.
  • Allogeneic stem cell transplant: A procedure where a patient receives blood-forming stem cells from a genetically similar donor to replace diseased bone marrow.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and eliminated.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent increasing the dose or require decreasing the dose in a clinical trial.

References

  1. https://clinicaltrials.gov/study/NCT04472598
  2. https://clinicaltrials.gov/study/NCT02520778
  3. https://clinicaltrials.gov/study/NCT01557777
  4. https://clinicaltrials.gov/study/NCT05054465
  5. https://clinicaltrials.gov/study/NCT05215405
  6. https://clinicaltrials.gov/study/NCT03592576